Profile

Julia Emerson, MD, MPH

Julia C. Emerson, MD, MPH, is an epidemiologist in the Division of Pulmonary Medicine at Seattle Children’s Hospital and lecturer in the Department of Pediatrics at the University of Washington School of Medicine. Emerson’s research interests include the natural history of early cystic fibrosis (CF) lung disease, the design of clinical trials to improve CF therapies and the development of better outcome measures for CF clinical protocols. She also collaborates on studies of the genotypic and phenotypic changes in airway pathogens that may be associated with CF lung disease severity and progression.

Overview

Research Focus Area

Translational Research

Publications

  • Rosenfeld M, Emerson J, McNamara S, Joubran K, Retsch-Bogart G, Graff GR, Gutierrez HH, Kanga JF, Lahiri T, Noyes B, Ramsey B, Ren CL, Schechter M, Morgan W, Gibson RL
    Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort.
    Pediatric pulmonology , 2010 Sept. : 934-44
  • Emerson J, McNamara S, Buccat AM, Worrell K, Burns JL
    Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008.
    Pediatric pulmonology , 2010 Apr, : 363-70
  • Sanders DB, Hoffman LR, Emerson J, Gibson RL, Rosenfeld M, Redding GJ, Goss CH
    Return of FEV1 after pulmonary exacerbation in children with cystic fibrosis.
    Pediatric pulmonology , 2010 Feb. : 127-34
  • Schechter MS, McColley SA, Silva S, Haselkorn T, Konstan MW, Wagener JS
    Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis.
    The Journal of pediatrics , 2009 Nov. : 634-9.e1-4
  • Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW
    Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
    Contemporary clinical trials , 2009 May : 256-68
  • Brannon MK, Davis JM, Mathias JR, Hall CJ, Emerson JC, Crosier PS, Huttenlocher A, Ramakrishnan L, Moskowitz SM
    Pseudomonas aeruginosa Type III secretion system interacts with phagocytes to modulate systemic infection of zebrafish embryos.
    Cellular microbiology , 2009 Feb. 6
  • Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, Ramsey BW
    Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.
    The Journal of pediatrics , 2009 Feb. : 183-8
  • Hoffman LR, Kulasekara HD, Emerson J, Houston LS, Burns JL, Ramsey BW, Miller SI
    Pseudomonas aeruginosa lasR mutants are associated with cystic fibrosis lung disease progression.
    Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society , 2009 Jan. : 66-70
  • Dovey M, Aitken ML, Emerson J, McNamara S, Waltz DA, Gibson RL
    Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study.
    Chest , 2007 Oct. : 1212-8
  • Ernst RK, Moskowitz SM, Emerson JC, Kraig GM, Adams KN, Harvey MD, Ramsey B, Speert DP, Burns JL, Miller SI
    Unique lipid a modifications in Pseudomonas aeruginosa isolated from the airways of patients with cystic fibrosis.
    The Journal of infectious diseases , 2007 Oct. 1 : 1088-92
  • Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, Acton J, Zeitlin P, Hiatt P, Moss R, Williams J, Ramsey BW
    Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis.
    Pediatric pulmonology , 2007 July : 610-23
  • Hoffman LR, Déziel E, D'Argenio DA, Lépine F, Emerson J, McNamara S, Gibson RL, Ramsey BW, Miller SI
    Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa.
    Proceedings of the National Academy of Sciences of the United States of America , 2006 Dec. 26 : 19890-5
  • Halbert CL, Miller AD, McNamara S, Emerson J, Gibson RL, Ramsey B, Aitken ML
    Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors.
    Human gene therapy , 2006 Apr, : 440-7
  • Moskowitz SM, Foster JM, Emerson JC, Gibson RL, Burns JL
    Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection.
    The Journal of antimicrobial chemotherapy , 2005 Nov. : 879-86
  • Standaert TA, Boitano L, Emerson J, Milgram LJ, Konstan MW, Hunter J, Berclaz PY, Brass L, Zeitlin PL, Hammond K, Davies Z, Foy C, Noone PG, Knowles MR
    Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials.
    Pediatric pulmonology , 2004 May : 385-92
  • Moskowitz SM, Foster JM, Emerson J, Burns JL
    Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
    Journal of clinical microbiology , 2004 May : 1915-22
  • Qin X, Emerson J, Stapp J, Stapp L, Abe P, Burns JL
    Use of real-time PCR with multiple targets to identify Pseudomonas aeruginosa and other nonfermenting gram-negative bacilli from patients with cystic fibrosis.
    Journal of clinical microbiology , 2003 Sept. : 4312-7
  • Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, Ramsey B
    Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
    American journal of respiratory and critical care medicine , 2003 Mar. 15 : 841-9
  • Aitken ML, Greene KE, Tonelli MR, Burns JL, Emerson JC, Goss CH, Gibson RL
    Analysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosis.
    Chest , 2003 Mar. : 792-9
  • Mayer-Hamblett N, Rosenfeld M, Emerson J, Goss CH, Aitken ML
    Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality.
    American journal of respiratory and critical care medicine , 2002 Dec. 15 : 1550-5
  • Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL
    Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.
    Pediatric pulmonology , 2002 Aug. : 91-100